Navigation Links
Scripps Florida scientists create new approach to destroy disease-associated RNAs in cells
Date:12/20/2012

JUPITER, FL, December 20, 2012 Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a new approach to alter the function of RNA in living cells by designing molecules that recognize and disable RNA targets. As a proof of principle, in the new study the team designed a molecule that disabled the RNA causing myotonic dystrophy.

The study, published online ahead of print on December 20, 2012 by the journal Angewandte Chemie, reports the creation of small molecules that recognize disease-associated RNAs, targeting them for destruction. Since small molecules are cell-permeable, the approach could have benefits over traditional methods of targeting RNAs for degradation, such as antisense or RNA interference (RNAi).

"We're excited about these results," said Matthew Disney, an associate professor at TSRI who pioneered the research. "This approach may allow for the inactivation of many cellular RNAs by small molecules and potentially lead the way to a whole range of novel therapeutics."

It's well known that gene expression can be controlled by triggering the degradation of messenger RNAthe blueprint for the production of proteins. This is accomplished through the recruitment of compounds that cleave or split the molecule. While several compounds can induce RNA cleavage in vitro, this has not been accomplished efficiently in living cellsuntil now.

In the new study, Disney and Research Associate Lirui Guan attached a rationally designed small molecule that targets the RNA that causes myotonic dystrophy type 1 with a molecule that produces hydroxyl radicals. Upon the small molecule's recognition of the target, a hydroxyl radical was released that cleaved the disease-associated RNA, alleviating the disease-associated defects. Disney noted that, despite the compound's producing a highly reactive species, the compounds are non-toxic at relatively effective doses.

The team accomplished this feat through what Disney calls a bottom-up approach to targeting RNA.

"We first identified the preferred RNA structural elements or motifs that bind to small molecules," he said. "Then we looked at these elements in RNAs that cause disease and designed a binding molecule with increased affinity and specificity for those elements."

Myotonic dystrophy type 1 involves a type of RNA defect known as a "triplet repeat," a series of three nucleotides repeated more times than normal in an individual's genetic code, resulting in a number of protein splicing abnormalities. Symptoms of this variable disease can include wasting of the muscles and other muscle problems, cataracts, heart defects and hormone changes.

The applications for this new approach could include cancer treatment in conjunction with other therapies, Disney said. The approach could also be used to create chemical probes of RNA function or to develop tools to probe RNA structureprovided, of course, that the RNA-binding preferences of the small molecules involved were well defined.


'/>"/>

Contact: Eric Sauter
esauter@scripps.edu
267-337-3859
Scripps Research Institute
Source:Eurekalert  

Related medicine news :

1. Scripps Florida scientists develop new compound that reverses fatty liver disease
2. Scripps Florida scientist awarded $2.5 million to study inner workings of memory formation
3. Scripps Florida scientists uncover a novel cooperative effort to stop cancer spread
4. Scripps Research Institute study points to potential new therapies for cancer and other diseases
5. 2 Scripps Research Institute scientists honored by American Chemical Society
6. Scripps studies show community-based diabetes programs are key to lowered costs and improved care
7. Scripps Research Institute receives $20 million to shed light on HIV drug resistance
8. Scripps Research Institute scientists show protein linked to hunger also implicated in alcoholism
9. Scripps Research scientists devise powerful new method for finding therapeutic antibodies
10. Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech
11. Scripps Florida scientists awarded nearly $1.5 million to develop new approaches to treat cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Florida scientists create new approach to destroy disease-associated RNAs in cells
(Date:5/2/2016)... ... 2016 , ... Dr. Rassouli, dentist in Orange County, CA comments ... research, which was published in the “Journal of the American Geriatrics Society,” more than ... Americans have Alzheimer’s disease. The study found that dental problems may increase the risk ...
(Date:5/2/2016)... ... , ... According to an American Psychological Association article, the Centers ... the age of 18. Of those who survive, many still face effects as they ... In her new book, Lyah! Lyah! Pants on Fyah!, she shares stories from women ...
(Date:5/2/2016)... ... May 02, 2016 , ... A research team, ... groundbreaking studies that determined that the adjustability and adaptability of pediatric support surfaces ... of pressure injuries, which are now referred to as “pressure injuries” by the ...
(Date:5/2/2016)... ... May 02, 2016 , ... MedaCheck, a ... and quality outcomes, has announced its partnership with GrandView Health Services. , With ... over the counter and prescription drug pharmacy services to thousands of residents. Serving ...
(Date:5/2/2016)... ... May 02, 2016 , ... One of Hollywood’s best kept ... Dermatology Surgery & Laser Center, in Milford, Penn. “Patients with busy lives want noninvasive ... fat treated and go home or back to work without having to wear recovery ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... , April 29, 2016 Automation ... science laboratory due to the growing demands for productivity ... technology, contemporary automated systems are already adept of a ... slow, tedious and manual labor. Instrumentation continues to evolve, ... even conceivable just a few years ago. Originally used ...
(Date:4/28/2016)... 2016  Marking its one year anniversary since ... cancer risk test, Color Genomics announced ... highly impact the most common hereditary cancers affecting ... Test analyzes hereditary cancer risks for breast, colorectal, ... The Color Test is physician ordered and includes ...
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
Breaking Medicine Technology: